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Abstract
b-blockers are widely used to improve symptoms and prolong life in heart disease primarily by inhibiting the actions of
endogenous catecholamines at the b1-adrenoceptor. There are two common naturally occurring polymorphisms within the
human b1-adrenoceptor sequence: Ser or Gly at position 49 in the N-terminus and Gly or Arg at position 389 in the C-
terminus and some clinical studies have suggested that expression of certain variants may be associated with disease and
affect response to treatment with b-blockers. The b1-adrenoceptor also exists in two agonist conformations - a high affinity
catecholamine conformation and a low affinity secondary agonist conformation. Receptor-effector coupling and
intracellular signalling from the different conformations may be affected by the polymorphic variants. Here, we examine
in detail the molecular pharmacology of the b1-adrenoceptor polymorphic variants with respect to ligand affinity, efficacy,
activation of the different agonist conformations and signal transduction and determine whether the polymorphic variants
do indeed affect this secondary conformation. Stable cell lines expressing the wildtype and polymorphic variants were
constructed and receptor pharmacology examined using whole cell binding and intracellular secondary messenger
techniques. There was no difference in affinity for agonists and antagonists at the human wildtype b1-adrenoceptor
(Ser49/Gly389) and the polymorphic variants Gly49/Gly389 and Ser49/Arg389. Furthermore, the polymorphic variant
receptors both have two active agonist conformations with pharmacological properties similar to the wildtype receptor.
Although the polymorphism at position 389 is thought to occur in an intracellular domain important for Gs-coupling, the
two agonist conformations of the polymorphic variants stimulate intracellular signalling pathways, including Gs-cAMP
intracellular signalling, in a manner very similar to that of the wildtype receptor.
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Introduction
b-blockers are widely used in the treatment of cardiovascular
disorders and as well as improving symptoms (e.g. ischaemic heart
disease and arrhythmias e.g. atrial fibrillation (AF)), they prolong
life in patients with heart failure and post-myocardial infarction
[1,2]. The beneficial properties appear to be through antagonism
of catecholamines at cardiac b-adrenoceptors (mainly b1-adreno-
ceptors) and the resulting reduction in rate and force of
contraction improves both short and long term outcomes [2–5].
There are two common naturally occurring polymorphisms
within the human b1-adrenoceptor; Serine (Ser) or Glycine (Gly)
at position 49 in the N-terminus [6,7] and Glycine (Gly) or
Arginine (Arg) at position 389 in the C-terminus [6,8,9]. Although
Ser49/Gly389 is known as the wildtype, the commonest variants
are Ser49 found in 72–88% population and Arg389 present in 54–
88% population (depending on ethnic origin, [1]).
At the cellular level, Gly49 b1-receptors appear to have a
greater propensity to agonist-induced desensitization and down-
regulation than Ser49 receptors [10,11] and thus Ser49 receptors
have been called the ‘‘more active’’ variant [1]. In some clinical
studies, Ser49 was associated with shorter survival in heart failure
[7,12,13], increased risk of AF [14], and greater response to b-
blockers [15,16]. Arg389 b1-adrenoceptors appear better coupled
to downstream Gs-cAMP signal transduction than Gly389 b1-
adrenoceptors [8,17]. Arg389 receptors have therefore been
proposed to be the ‘‘more active’’ polymorphism. In some studies,
this greater effector coupling of Arg389 receptors results in an
increased heart rate, contractility and cardiac output in people in
response to agonists compared to those with Gly389 [18,19].
Arg389 individuals also have a greater response to b-blockers than
Gly389 individuals [15,20,21]. In heart failure, some studies
suggest that patients with Arg389 receptors have a longer survival
[22] and a more beneficial response to b-blockers than those with
Gly389 receptors [23–28]. In AF, patients with Gly389 receptors
have a better response to b-blocker rate control than those with
Arg389 receptors [29,30] but ventricular arrhythmias appear to be
more readily prevented in Arg389 than Gly389 patients [31].
However, there are also contrasting studies in the literature that
did not find associations between genotype and disease outcome or
response to treatment [1,2,5,32–36]. There may be several
explanations for this: the dose of b-blocker administered may
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not have been sufficient for the more active Ser49 and Arg389
receptor patients [12,13,37] or it may be due to the different b-
blockers used in trials [15,16,20,27,30,32].
At the molecular pharmacology level, the b1-adrenoceptor is
known to exist in at least two agonist conformations: 1) a high affinity
‘‘catecholamine’’ conformation where agonist responses are readily
inhibited by b-blockers and 2) a secondary low affinity agonist
conformation where higher concentrations of b-blockers are needed
to inhibit agonist responses [26,38–41]. Interestingly, several
clinically used b-blockers interact with this secondary conformation
of the b1-adrenoceptor [42–46] and many b-blockers have been
shown elicit agonist responses via this conformation [43–48].
A previous study has suggested that the coupling or signalling
efficiency of this secondary conformation is affected by the
polymorphic variant of the b1-adrenoceptor. The secondary
conformation agonist CGP 12177 ((-)-4-(3-tert-butylamino-2-
hydroxypropoxy)-benzimidazol-2-one) has been reported to be a
very weak partial agonist at Arg389 receptors, whereas it was a full
agonist at Gly389 receptors [17]. This suggests that the agonist
efficacy of several clinically used b-blockers could vary between the
different polymorphic variants of the human b1-adrenoceptor.
Here, we examine in detail the molecular pharmacology of the
b1-adrenoceptor polymorphic variants with respect to ligand
affinity and efficacy and we determine whether there are any
differences in the molecular pharmacology between the catechol-
amine and secondary conformations of the wildtype and
polymorphic variants of the human b1-adrenoceptor.
Results
3H-CGP 12177 whole cell binding
Saturation binding revealed that 3H-CGP 12177 bound
specifically to the wildtype b1-adrenoceptor (Ser49/Gly389) in
the stable cell line with an affinity (KD value) of 0.3660.04 nM
(receptor expression level 611698 fmol/mg protein, n = 11). The
affinity of 3H-CGP 12177 was similar in the b1Gly49/Gly389 cell
line (KD = 0.3860.03 nM, 819675 fmol/mg protein n = 10) and
in the b1Ser49/Arg389 cells (KD = 0.4560.04 nM, 10686
142 fmol/mg protein n = 9). The binding affinities for several
b-agonists and antagonists were then assessed by competition
binding (Figure 1, Table 1).
3H-cAMP accumulation
Adrenaline and noradrenaline stimulated agonist responses at
the wildtype b1-adrenoceptor and acted as full agonists relative to
isoprenaline. Similar responses were seen in the Gly49/Gly389
and Ser49/Arg389 cell lines (Table 2). Cimaterol, an agonist
known to stimulate responses via the high affinity catecholamine
conformation of the wildtype receptor [45], stimulated slightly
submaximal responses, and CGP 12177, a known secondary or
low affinity conformation agonist, produced sub-maximal respons-
es at all three receptors (Figure 2, Table 2). To confirm that these
responses were occurring at the different conformations of the b1-
adrenoceptor, they were inhibited by the b1-selective antagonist
CGP 20712A and two common clinically used b-blockers,
bisoprolol and carvedilol (Figure 2, Table 3). Inhibition of the
cimaterol responses required low concentrations of b-blockers
consistent with an interaction with the high affinity conformation,
whereas inhibition of CGP 12177 responses required significantly
higher concentrations of antagonist as required for the secondary
low affinity conformation in all three cell lines.
CGP 12177 is known to be a high affinity antagonist of the
catecholamine conformation of the wildtype b1-adrenoceptor and
inhibited the cimaterol response at very low concentrations to give
Figure 1. Inhibition of 3H-CGP 12177 binding at the wildtype
receptor and polymorphic variants. Inhibition of 3H-CGP 12177
specific binding by A metoprolol and B carvedilol in wildtype (WT),
Gly49/Gly389 cells and Ser49/Arg389 cells. Non-specific binding was
determined by 10 mM propranolol. The concentration of 3H-CGP
12177 present in each case was 0.96 nM. Data points are mean 6
s.e.mean of triplicate determinations and these single experiments
are representative of 6 separate experiments in each case. C
Correlation plot for the affinity of all the ligands from Table 1 for
the wildtype (x-axis) and polymorphic variants (y-axis). There is a
strong correlation between the affinity measurements made in the
wildtype and those measured in either the Gly49/Gly389 receptor
(R2 = 1.00, slope 0.9960.01) and the Ser49/Arg389 receptor (R2 = 0.99,
slope = 0.9260.02). This demonstrates that ligands had very similar
affinity for all three receptors.
doi:10.1371/journal.pone.0077582.g001
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high affinity KD values for CGP 12177 (Figure 3, Table 3). High
affinity antagonism of cimaterol can also be seen in Figure 4,
where CGP 12177 (1–10 nM) inhibited the response to 30 nM
cimaterol whereas 100 nM was required to achieve the maximum
response to CGP 12177. A similar pattern was seen for both
polymorphic variants of the receptor.
The efficacy of other b-blockers used in clinical practice were then
examined at the different polymorphic variants (Table 2). At the
wildtype receptor, several ligands are known to stimulate both the
high and low affinity conformations and yield biphasic concentration-
response curves [43,46,53]. In the wildtype receptor, CGP 12177
produced a lower response than that mediated by the catecholamine
conformation response to isoprenaline. However a previous phar-
macological study found that at the secondary conformation of
Arg389 receptors, CGP 12177 responses were very weak (5% that of
the catecholamine conformation responses) whilst CGP 12177
responses were equally efficacious, stimulating the same size response
as isoprenaline at Gly389 receptors [17]. A ligand with a biphasic
concentration response in the wildtype receptor should therefore
appear monophasic at the Arg389 receptor as the efficacy of ligands
at the secondary conformation is so low as to be barely detectable.
Here, however, similar biphasic responses were seen at the wildtype
and both polymorphic variants of the receptor (Figure 5; Table 4).
Evidence of other G-protein coupling or signal
transduction pathways
As the b1-adrenoceptor has been shown to have biased
signalling [54], and the 389 polymorphism is in the region
involved in G-protein coupling and signal transduction [55], the
involvement of other signalling cascades was investigated.
Pre-incubation with pertussis toxin (PTX) completely inhibited
the Gi-coupled inhibition of 3H-cAMP accumulation in response
to cyclopentyadenosine (CPA) in CHO cells expressing the human
adenosine A1 receptor (Figure 6). However, it had no effect on the
cimaterol or CGP 12177 responses at the WT, Gly49/Gly389 or
Ser49/Arg389 receptors in experiments run on the b1-adreno-
ceptors in parallel experiments (Figure 6). In addition, PTX had
no effect on the biphasic concentration response to pindolol (data
not shown).
Signalling via the Gq pathways was examined using 3H-inositol
phosphate accumulation. Here 100 mM UTP and 100 mM ATP
stimulated responses via the endogenous P2y2 receptors [56] that
were 1.8760.11 and 2.1860.17 n = 4 fold over basal at the
wildtype Ser49/Gly389 receptor, 2.3260.29 and 2.7760.40,
n = 4 at the Gly49/Gly389, and 2.6360.40 and 2.9660.28 n = 4
in the Ser49/Arg389 b1-receptors respectively. Even though the
transfected b1-adrenoceptors were highly expressed, no agonist
responses were seen to cimaterol (catecholamine conformation
agonist), CGP 12177 (secondary conformation agonist), or
pindolol (agonist at both conformations; Figure S1).
Finally, the potential for direct activation of the MAPKinase
pathway was investigated using the Alphascreen Surefire MAPKi-
nase assay. A time course was performed on all three receptors in
case the maximum response occurred at different times for the two
different agonist conformations of the receptor and for the positive
control (phorbol ester). The maximum stimulation to 1 mM
phorbol ester occurred at 30 minutes and was 11.961.6,
Table 1. Affinity of b-adrenoceptor ligands for the wildtype and polymorphic variants of the b1-adrenoceptor.
WT (Ser49/Gly389) n Gly49/Gly389 n Ser49/Arg389 n
Adrenaline 24.9660.08 6 24.9660.04 6 25.3360.07## 6
Atenolol 26.84 0.05 6 26.8560.05 6 26.7360.07 11
Bisoprolol 28.0360.05 5 28.0160.09 5 27.9860.04 5
Bucindolol 29.5660.05 6 29.4760.02 6 29.4660.03 6
Carvedilol 29.3460.03 6 29.2560.02 6 29.2660.05 6
CGP 20712A 28.8760.07 7 28.8060.07 7 28.6560.10 6
Cimaterol 26.3960.08 6 26.5160.09 5 26.5560.02 5
ICI 118551 26.8760.06 6 26.8360.03 6 26.7360.02 6
Isoprenaline 26.1160.07 6 26.0760.07 6 26.3760.10 3
Metoprolol 27.5560.02 6 27.5660.03 6 27.5060.04 6
Noradrenaline 25.5360.07 6 25.5960.04 6 25.9960.08### 6
Nebivolol 29.3560.06 6 29.3460.07 6 29.2560.07 6
Pindolol 28.7160.08 6 28.6760.08 6 28.6860.09 6
Propranolol 28.2760.04 6 28.2360.03 6 28.2160.03 11
Terbutaline 23.9960.04 6 23.8360.05# 6 24.0860.05 5
Xamoterol 27.2560.09 7 27.1960.03 7 27.1760.05 7
Log KD values obtained from
3H-CGP 12177 whole cell binding in cells expressing either the human wildtype b1-adrenoceptor or the polymorphic variants. KD values are
mean 6 s.e.mean for n separate experiments.
One-way ANOVA with post hoc Neuman-Keuls was performed comparing the affinities obtained for the wildtype receptor with those obtained for each polymorphic
variant in turn.
#=p,0.05,
##=p,0.01,
###=p,0.001.
Statistically significant differences in affinities between the receptor polymorphisms were not seen in transiently transfected cells nor in all stable cell lines (Table S1 and
S2 in File S1).
CGP 20712A (2-hydroxy-5-(2-[{hydroxy-3-(4-[1-methyl-4-trifluoromethyl-2-imidazolyl]phenoxy)propyl}amino]ethoxy)benzamide).
ICI 118551 ((-)-1-(2,3-[dihydro-7-methyl-1H-inden-4-yl]oxy)-3-([1-methylethyl]-amino)-2-butanol).
doi:10.1371/journal.pone.0077582.t001
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12.663.8 and 7.461.4, n = 3, fold over basal in the wildtype,
Gly49/Gly389 and Ser49/Arg389 receptors respectively. Once
again, although the transfected b1-adrenoceptors were highly
expressed, no agonist responses were seen to cimaterol, CGP
12177, or pindolol (Figure S2).
Impact of expression level - transient transfection and
other cell lines
Using single stable cell lines to draw conclusions about receptor-
effector coupling is difficult as each cell line is a unique entity – for
example the place of insertion of the transfected DNA into the
genome is unique in each line and may affect the expression of
other genes as well as the expression of the receptor itself. As the
main finding of this study differs from that previously published
(with regard to the ability of the two agonist conformations to
couple to downstream effectors) two further stable cells lines
expressing either the wildtype receptor, Gly49/Gly389 or Ser49/
Arg389 variants were also established. The responses obtained
were very similar (see Tables S1, S3 and S4 in File S1, Figure S3).
Also data similar to Figure 4 was obtained in all 9 cell lines. In
addition, 3 or 4 separate transiently transfected populations of cells
were examined for each of the wildtype receptor, Gly49/Gly389
or Ser49/Arg389 variants. Both variant receptors showed similar
responses in terms of affinity (KD) and efficacy (EC50 and %
maximum response) as the wildtype receptor (see Tables S2 and
S3 in File S1). Thus similar data were found in 3 stable cell lines of
the wildtype and each polymorphic variant and in 3–4 transiently
transfected populations of each receptor.
Discussion
Recent pharmacological and clinical studies have suggested that
there are differences in cellular responses and clinical outcomes
depending on which of the naturally occurring polymorphisms of
the human b1-adrenoceptor are present. Here, we studied the
wildtype human b1-adrenoceptor and its common polymorphic
variants in detail, paying particular attention to the pharmacology
of the two active conformations of the human b1-adrenoceptor -
the high affinity catecholamine conformation and the low affinity
secondary CGP 12177 conformation.
Firstly, the affinity with which agonists and antagonists bind to
the wildtype receptor (Ser49/Gly389) and the two common
polymorphic variants Gly49 and Arg389 was assessed by 3H-CGP
12177 whole cell binding. The affinity of ligands for the
extracellular Ser49 and Gly49 polymorphic variants of the
receptors [11] and the intracellular Gly389 and Arg389 variants
[17] have previously been reported to be very similar. In keeping
with these previous studies, the binding affinities of all ligands were
found to be very similar across all three receptors variants
(Figure 1, Table 1 and Figure S3, Table S1 and S2 in File S1 for
other cell lines and transient transfections), suggesting that
differences in affinity are not the explanation for the differences
in clinical responses to b-blocker treatment seen in clinical trials.
The efficacy of ligands was then assessed by examining the
primary signal transduction pathway: b1-Gs-coupled stimulation
of cAMP. At the wildtype b1-adrenoceptor and both polymorphic
variants, the endogenous catecholamine noradrenaline was more
potent (left-shifted agonist concentration response) than adrenaline
in keeping with expected b1-adrenoceptor activity (Table 2).
When the responses to several partial agonists were examined
(Table 2), it appears that the responses seen at the Ser49/Arg389
receptor were of greater efficacy (% maximum response and left-
shifted EC50). This could be because of the higher receptor
expression level in the Ser49/Arg389 cell line relative to the
wildtype and Gly49/Gly389 cell lines or due to better coupling of
the Ser49/Arg389 receptor to the Gs-cAMP effector system
[8.17]. A change in the expression level of the wildtype receptor
(from 219 to 2084 fmol/mg protein) causes a linear increase in the
efficacy (% isoprenaline maximum response) of partial agonists
(Table S5 in File S1) however this was not as clear in cell lines
expressing the polymorphic variants where a smaller change in
receptor expression level was achieved. It is therefore difficult to
tease out whether the increased efficacy seen in the main Ser49/
Arg389 cell line is indeed due to increased coupling efficiency or
Table 2. Agonist responses at the wildtype and polymorphic variants of the b1-adrenoceptor.
WT Ser49/Gly389 Gly49/Gly389 Ser49/Arg389
Log EC50 % isop n Log EC50 % isop n Log EC50 % isop n
Adrenaline 26.6860.26 96.462.1 5 26.5960.17 95.963.2 5 26.9260.24 91.662.2 5
Noradrenaline 27.0760.20 95.562.0 5 27.0060.25 99.163.7 5 27.4860.26 96.063.0 5
Cimaterol 27.9060.07 73.261.7 13 27.9160.03 77.461.1 15 28.5160.04# 87.161.6# 15
CGP 12177 27.8660.04 34.862.7 13 27.6960.03# 36.061.3 12 28.1160.08# 59.161.6# 13
CGP 20712A No resp 0 4 No resp 0 4 No resp 0 4
Bisoprolol No resp 0 4 No resp 0 4 No resp 0 4
Metoprolol No resp 0 4 No resp 0 4 27.6660.10 0.760.1 4
Atenolol No resp 0 4 No resp 0 4 27.2160.13 1.360.2 3
Nebivolol 29.8360.20 1.3160.3 5 29.4260.09 1.1660.1 5 29.5260.13 3.660.3# 5
Xamoterol 28.1360.06 28.062.4 7 27.9660.06 29.464.5 9 28.0560.10 52.164.5# 9
Log EC50 values and % isoprenaline maximal responses obtained from
3H-cAMP accumulation in cells expressing either the human wildtype b1-adrenoceptor or the
polymorphic variants. Values are mean 6 s.e.mean of n separate determinations.
One-way ANOVA with post hoc Neuman-Keuls was performed comparing the log EC50 values and % maximum isoprenaline responses obtained for the wildtype
receptor with those obtained for each polymorphic variant in turn.
#=p,0.05.
The log EC50 values and % maximum isoprenaline responses for the partial agonists cimaterol, CGP 12177, nebivolol and xamoterol are significantly different for the
Ser49/Arg389 receptor compared with wildtype. This could be due to either the higher receptor expression level of the Ser49/Arg389 cell line or more efficient receptor-
effector coupling of the Ser49/Arg389 receptors (see Discussion for further detail).
doi:10.1371/journal.pone.0077582.t002
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increased receptor expression level, or a combination of both.
Transiently transfected studies however showed no change in
partial agonist efficacy (see Table S3 in File S1). Whatever the
reason, the increased efficacy unveils small agonist responses in
this cell line, e.g. to atenolol and metoprolol, that are not visible at
the other receptors.
The main aim of this study was to examine the pharmacological
responses at the two agonist conformations of the b1-adrenocep-
tor. Cimaterol (a catecholamine, high affinity conformation
agonist [45]) and CGP 12177 (a secondary, low affinity
conformation agonist) both stimulated responses in the wildtype
and both polymorphic variants (Table 2). However, whereas the
cimaterol responses were antagonised by low concentrations of
antagonists, much higher concentrations of antagonist were
needed to antagonise the CGP 12177 response at all three
receptors (Table 3 and Figure 2) in keeping with previous studies
[17]. Secondly, low concentrations of CGP 12177 were able to
inhibit the cimaterol response, thus leading to log KD values of
29.90, 29.90 and 29.83 at the wildtype, Gly49/Gly389 and
Ser49/Arg389 receptors respectively (Figure 3, Table 3) whereas
the log EC50 values for the agonist responses stimulated by CGP
12177 were 27.86, 27.69 and 28.11. As the affinity (KD) and
EC50 should be the same for a partial agonist interacting with a
receptor at the same conformation, this suggests that CGP 12177
Figure 2. Inhibition of 3H-cAMP accumulation responses to cimaterol and CGP 12177 at the wildtype and polymorphic variant
receptors. 3H-cAMP accumulation in response to cimaterol and CGP 12177 in A and D wildtype (WT) cells, B and E Gly49/Gly389 cells and C and F
Ser49/Arg389 cells in the absence and presence of bisoprolol and carvedilol. Bars represent basal 3H-cAMP accumulation, that in response to 10 mM
isoprenaline and that in response to 30 nM bisoprolol or 3 nM carvedilol for A, B and C or 10 mM bisoprolol or 1 mM carvedilol for D, E and F. Data
points are mean6 s.e.mean of triplicate determinations and these single experiments are representative of 4 separate experiments in each case. This
demonstrates the difference in the affinity of antagonists for the catecholamine (high affinity) conformation and secondary (low affinity)
conformation of the receptors and that both of these conformations exist in all receptor variants.
doi:10.1371/journal.pone.0077582.g002
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is acting through two different conformations of the receptor.
Thirdly, CGP 12177 was able to inhibit the stimulatory response
to cimaterol at concentrations lower than that required for it to
stimulate an agonist response on its own (Figure 4). Taken
together, therefore, this confirms that the two agonist conforma-
tions are present in both polymorphic variants as well as the
wildtype b1-adrenoceptor.
Previous studies have, however, suggested that although both
the high and low affinity conformations exist, they are coupled
differently in the polymorphic variants. Joseph et al [17] found
that whilst the isoprenaline response was greater in the Arg389
receptor compared to the Gly389 receptor (in keeping with greater
Arg389 downstream coupling), CGP 12177 was a very weak
partial agonist at the Arg389 receptor (5% response compared
with isoprenaline) but stimulated full agonist response (105%
compared with isoprenaline) at the Gly389 receptor. Also
isoprenaline was found to be significantly more potent (EC50
value 100 times left-shifted) at the Gly389 receptor [17]. They
therefore suggested that there were different modes of coupling for
the catecholamine conformation and secondary conformation of
the receptor.
Here, CGP 12177 stimulated agonist responses that were
34.8%, 36.0% and 59.1% of isoprenaline at the wildtype, Gly49/
Gly389 and Ser49/Arg389 receptors respectively (Table 2,
Figure 2), and thus were in proportion to that seen for other
partial agonists (including xamoterol, previously been shown to be
a catecholamine conformation partial agonist, [45]). This was also
true for the other cell lines and the transient transfections (Table
S3 and S4 in File S1). There is therefore no evidence here for
differential secondary conformation coupling.
To examine this further, ligands that have agonist actions at
both conformations of the b1-adrenoceptor (pindolol, carvedilol
and bucindolol) were investigated (Table 4, Figure 5). These
ligands have a biphasic concentration response where the first part
of the response (low concentration) is thought to occur at the high
affinity conformation as it is readily inhibited by antagonists while
the second part of the response occurring at higher concentration
is considered to be occurring at the low affinity secondary
conformation of the receptor [43,46,53]. If the Arg389 primary
conformation coupled well, and the secondary conformation very
poorly, very little stimulation would be occurring via this
secondary conformation and the concentration response curve
should become monophasic. This was however not the case, and
biphasic concentration response curves were seen at each
polymorphic variant, for all the stable cell lines and the transient
transfections (Table 4 and Table S4 in File S1). Furthermore, the
proportions of the response occurring at each conformation was
very similar across all the receptors. This once again suggests that
the CGP 12177 secondary conformation couples to Gs-cAMP
effectors in the wildtype and different polymorphic variants of the
b1-adrenoceptor in a similar manner.
Finally, as the 389 polymorphism is within the intracellular Gs-
coupling domain of the receptor and the Gly389 is thought to alter
the a-helix of that region and therefore disrupt signalling [55], the
ability of the wildtype and polymorphic variants to induce
intracellular signalling via different mechanisms was examined,
including other potential G-protein and non-G-protein coupled
signalling [54,57–59]. Pre-incubation with PTX, which prevents
Gi/o-protein coupling by ADP ribosylating the Gai/o subunit,
had no effect on the cimaterol, CGP 12177 or biphasic pindolol
responses, suggesting that coupling to Gi-proteins was not involved
in the coupling of the catecholamine or secondary conformation
responses in the wildtype or polymorphic variants. Similarly,
cimaterol, CGP 12177 and pindolol did not stimulate an increase
in 3H-inositol phosphate accumulation nor an increase in ERK1/
2 MAPKinase activation. Therefore the polymorphic variants do
not appear to differ in their ability to signal to other intracellular
pathways.
In conclusion, this study suggests that there is no difference in
affinity for agonists and antagonists at the human wildtype b1-
adrenoceptor (Ser49/Gly389) and the polymorphic variants at
positions Gly49/Gly389 and Ser49/Arg389. Furthermore, the
polymorphic variant receptors both have two active agonist
conformations with pharmacological properties the same as those
of the wildtype receptor. Although the 389 polymorphism is
thought to occur in an intracellular domain important for Gs-
coupling, the two agonist conformations of the polymorphic
variants stimulate intracellular signalling pathways, including Gs-
cAMP intracellular signalling, in a manner very similar to that of
the wildtype receptor.
Materials and Methods
Materials
Foetal calf serum which was from PAA Laboratories (Tedding-
ton, Middlesex, UK). Microscint 20 and Ultima Gold XR
Table 3. Affinity of antagonists for the two agonist conformations of the wildtype and polymorphic variants of the b1-
adrenoceptor.
KD bisoprolol n KD CGP 20712A n KD carvedilol n KD CGP 12177 n
Cimaterol as agonist
WT Ser49/Gly389 28.7760.08 4 29.8560.07 7 210.3060.05 4 29.9060.07 8
Gly49/Gly389 28.6060.04 5 29.8360.08 14 210.2260.07 4 29.9060.05 8
Ser49/Arg389 28.6560.06 5 29.7860.03 13 210.2960.03 4 29.8360.05 6
CGP 12177 as agonist
WT Ser49/Gly389 25.7260.04 5 27.3560.06 8 27.5560.08 5
Gly49/Gly389 25.7060.06 5 27.3760.05 16 27.7360.14 5
Ser49/Arg389 26.0460.12 5 27.4660.05 15 27.9360.10 5
Log KD values for bisoprolol, CGP 20712A, carvedilol and CGP 12177 obtained from
3H-cAMP accumulation the human wildtype b1-adrenoceptor or the polymorphic
variant. Values are mean 6 s.e.mean. of n separate determinations. The concentrations of antagonist use were: bisoprolol 30 nM when cimaterol was the agonist and
10 mM when CGP 12177 was the agonist; CGP 20712A 3 nM and 30 nM with cimaterol and 1 mM and 10 mM with CGP 12177; carvedilol 3 nM with cimaterol and 1 mM
with CGP 12177; and CGP 12177 was at 1 nM and 10 nM when cimaterol was the agonist.
doi:10.1371/journal.pone.0077582.t003
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scintillation fluids were from PerkinElmer (Shelton, CT, USA).
3H-CGP 12177, 3H-adenine, 14C-cAMP and 3H-myo-inositol
were from Amersham International (Buckinghamshire, UK).
Bisoprolol, bucindolol, carvedilol, and cimaterol were from Tocris
Life Sciences (Avonmouth, UK). Nebivolol was a gift from Stefano
Evangelista (Menarini Ricerche Spa, Florence, Italy). The Surefire
Alphascreen pERK1/2 kit was obtained from PerkinElmer. All
other reagents were from Sigma Chemicals (Poole, Dorset, UK).
Generation of human b1-adrenoceptor polymorphic
variants
The cDNA sequence encoding the human b1-adrenoceptor in
pJG3.6 was a gift from Steve Rees (GlaxoSmithKline, Stevena-
ge,UK). This cDNA was subcloned as a HindIII/XbaI fragment
into pcDNA3.1 (Invitrogen) and the sequence was confirmed by
DNA sequencing. The wild-type (WT) b1-adrenoceptor sequence
Figure 3. Inhibition of cimaterol-induced 3H-cAMP accumula-
tion responses by CGP 12177. 3H-cAMP accumulation in response
to cimaterol in A wildtype cells, B Gly49/Gly389 cells and C Ser49/
Arg389 cells in the absence and presence of CGP 12177. Bars represent
basal 3H-cAMP accumulation, that in response to 10 mM isoprenaline
and that in response to 1 nM and 10 nM CGP 12177. Data points are
mean 6 s.e.mean of triplicate determinations and these single
experiments are representative of 4 separate experiments in each case.
Here, CGP 12177 inhibits the catecholamine conformation response
with high affinity in all three receptor variants.
doi:10.1371/journal.pone.0077582.g003
Figure 4. Demonstration of two agonist conformations of the
wildtype b1-adrenoceptor and polymorphic variants. 3H-cAMP
accumulation in response to CGP 12177 in A wildtype cells, B Gly49/
Gly389 cells and C Ser49/Arg389 cells in the absence and presence of
30 nM cimaterol. Bars represent basal 3H-cAMP accumulation, that in
response to 10 mM isoprenaline and that in response to 30 nM
cimaterol. Data points are mean6 s.e.mean of triplicate determinations
and these single experiments are representative of 5 separate
experiments in each case. Low concentrations of CGP 12177 inhibit
the high affinity catecholamine conformation and higher concentra-
tions of CGP 12177 stimulate an agonist response. This demonstrates
the two agonist conformations of the wildtype b1-adrenoceptor and
that both of these agonist conformations are present in both
polymorphic variants.
doi:10.1371/journal.pone.0077582.g004
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was confirmed to contain the Ser49 and Gly389 polymorphisms.
Ser49Gly and Gly389Arg mutations were generated using the
QuikChange mutagenesis kit (Stratagene, La Jolla, CA) and
Bioline PolyMate Additive for GC-rich templates. Mutants are
named as (wild-type residue)(residue number)(mutant residue).
The sequence of the forward (F) and reverse (R) complementary
oligonucleotide primers (59 to 39) used to synthesize a b1-
adrenoceptor cDNA sequence containing the relevant mutations
(indicated in bold) were as follows:
S49Gb1-F CGCCAGCGAAGGCCCCGAGCCGC
S49Gb1-R GCGGCTCGGGGCCTTCGCTGGCG
G389Rb1-F CAAGGCCTTCCAGCGACTGCTCTGCTGCG
G389Rb1-R CGCAGCAGAGCAGTCGCTGGAAGGCCTTG
After subcloning in Top F9 competent cells (Invitrogen), the
mutant b1-adrenoceptor cDNA was excised on HindIII/XbaI and
subcloned into native pcDNA3.1 containing a neomycin selection
marker. All mutations and sequences were confirmed by DNA
sequencing.
Cell lines and cell culture
Chinese Hamster Ovary (CHO) cells were transfected with
either the wildtype (WT) human b1-adrenoceptor (Ser49/
Gly389) or each polymorphic variant in turn, either Gly49/
Gly389 or Ser49/Arg389. The Gly49/Gly389 receptor rarely
exists in humans [5]. The cells were selected for 3 weeks using
resistance to geneticin (1 mg/ml) and stable cells lines were
generated by dilution cloning. Where Gi-coupling was exam-
ined, CHO cells stably expressing the human adenosine A1
receptor (CHO-A1, [49]) were used as a control in each
experiment to demonstrate that pertussis toxin (PTX) was
indeed effective. All cells were grown in Dulbecco’s modified
Eagle’s medium nutrient mix F12 (DMEM/F12) containing
10% foetal calf serum and 2 mM L-glutamine in a 37uC
humidified 5% CO2 : 95% air atmosphere.
3H-CGP 12177 Whole Cell Binding
Cells were grown to confluence in white-sided tissue culture
treated 96-well view plates and 3H-CGP 12177 whole cell
saturation and competition binding was performed as previously
described [46]. Briefly, 100 ml competing ligand in serum free
media at twice the final required concentration was added to each
well followed immediately by a 100 ml of 3H-CGP 12177 (giving a
1:2 dilution in the well) and the plates incubated for 2 hours at
37uC, 5% CO2, humidified atmosphere. The cells were washed
twice with 200 ml 4uC phosphate buffered saline, 100 ml Micro-
scint 20 was added to each well, and the plates counted on a
Topcount at 21uC for 2 minutes per well. Propranolol (10 mM)
was used to define non-specific binding and 3H-CGP 12177 in the
concentration range of 0.75–2.67 nM was used for competition
assays and (0.005–46.7 nM) for saturation assays. Protein concen-
tration was determined by the method of Lowry et al. [50].
3H-cAMP accumulation
Cells were grown to confluence in clear plastic tissue culture
treated 24-well plates and 3H-cAMP accumulation performed as
previously described [46]. Briefly, cells pre-labelled with 3H-
adenine by incubation for 2 hours with 2 mCi/ml 3H-adenine in
serum-free media (0.5 ml per well). The cells were washed, then
1 ml serum-free media containing 1 mM IBMX (3-isobutyl-1-
methylxanthine) was added to each well and the cells incubated
for 15 minutes. Agonists (in 10 ml serum-free media) were added
to each well and the plates incubated for 5 hours in order to
maximise the responses [46]. The assay was terminated by
adding 50 ml concentrated HCl per well, the plates frozen,
thawed and 3H-cAMP separated from other 3H-nucleotides by
sequential Dowex and alumina column chromatography. Where
CGP 12177 and cimaterol were co-incubated with the cells, the
two ligands were added simultaneously. Where pertussis toxin
(PTX) was used, cells were incubated in the 24 well plates with
PTX at 100 ng/ml for 24 hours before experimentation. The
response to cyclopentyladenosine (CPA) in the absence and
presence of PTX was examined in CHO-A1 cells alongside
every experiment to demonstrate that PTX was preventing Gi-
coupled responses. 10 mM isoprenaline (or 10 mM forskolin in
CHO-A1 cells) was used to define the maximal response in each
experiment.
Figure 5. 3H-cAMP accumulation in response to pindolol at the
wildtype b1-adrenoceptor and polymorphic variants. 3H-cAMP
accumulation in response to pindolol in A wildtype cells, B Gly49/
Gly389 cells and C Ser49/Arg389 cells. Bars represent basal 3H-cAMP
accumulation and that in response to 10 mM isoprenaline. Data points
are mean 6 s.e.mean of triplicate determinations. These single
experiments are representative of 5 separate experiments in each case
and demonstrate agonist actions at both agonist conformations of the
b1-adrenoceptor in the wildtype and polymorphic variants.
doi:10.1371/journal.pone.0077582.g005
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3H-inositol phosphate accumulation
Cells were grown to confluence in clear plastic tissue culture
treated 24-well plates containing 3H-myo-inositol (4 mCi/ml).
Cells were washed then incubated for 30 minutes in 1 ml of serum
free media containing 20 mM LiCl (37uC, 5% CO2). Agonists (in
10 ml) were then added and the incubation continued for 1 hour.
All reagents were then removed and 1 ml of cold (220uC)
methanol/0.12M HCl (1:1, v/v) added to each well. The plates
were stored at 220uC overnight before isolating total 3H-inositol
phosphates as described previously [51]. Total 3H-inositol
phosphate levels were determined by liquid scintillation counting.
100 mM ATP and 100 mM UTP was used as positive controls.
MAPKinase - phospho ERK1/2
Extracellular-signal-regulated kinases ERK1/2 activation was
measured using a Surefire Alphascreen pERK1/2 kit as per
manufacturer’s instructions. Briefly, cells were grown to conflu-
ence in clear plastic tissue culture treated 96-well plates then serum
starved by incubation in serum-free media for 24 hours before
experimentation. Agonist in 20 ml was added to the well (1:5
dilution in wells) and incubated for 5–60 minutes (37uC, 5% CO2).
Reagents were then removed and 20 ml lysis buffer added to each
well. Plates were frozen at 220uC overnight, thawed, and the
assay then conducted as per manufacturer’s instructions. After
2 hours in the dark, the plates were read on an Envision plate
reader using standard Alphascreen settings. 1 mM phorbol ester
was used as the positive control.
Data analysis
Whole cell binding - Saturation binding. To determine the
binding affinity (KD value) for
3H-CGP 12177 and the receptor
expression level, saturation binding curves of the total and non-
specific binding (as determined by the presence of 10 mM
propranolol) were performed with all data points in quadruplicate.
Specific binding (SB, equation 1) of 3H-CGP 12177 at different
concentrations of the 3H-ligand was plotted using the non-linear
regression program Prism 2 to the equation:
SB~
AxBMAXð Þ
AzKDð Þ ð1Þ
where A is the concentration of 3H-CGP 12177, BMAX is the
maximal specific binding and KD is the dissociation constant of
3H-CGP 12177.
Whole cell binding - Competition binding. In all cases, the
competing ligand completely inhibited the specific binding of 3H-
CGP 12177. All data points were performed in triplicate and each
96-well plate also contained 6 determinations of total and non-
specific binding. A one-site sigmoidal response curve was then
fitted to the data using Graphpad Prism 2.01 and the IC50 was
then determined as the concentration required to inhibit 50% of
the specific binding.
% of uninhibited binding~100{
(100xA)
AzIC50
zNS ð2Þ
where A in the concentration of the competing ligand, IC50 is the
concentration at which half of the specific binding of 3H-CGP
12177 has been inhibited, and NS is the non-specific binding.
From the IC50 value and concentration of radioligand [
3H-CGP
12177], the KD value (concentration at which half the receptors
are bound by the competing ligand) was calculated using the
equation:
KD~
IC50
1z 3H{CGP12177½ KD3H{CGP12177  ð3Þ
Functional assays - 3H-cAMP accumulation. Most agonist
responses were best described by a one-site sigmoidal concentra-
tion response curve (equation 4)
Response~
EMAXx½A
EC50z½A ð4Þ
Where Emax is the maximum response, [A] is the agonist
concentration and EC50 is the concentration of agonist that
produces 50% of the maximal response
The affinities of antagonists (KD values, Table 3) were
calculated from the shift of the agonist concentration response
curve in the presence of a fixed concentration of antagonist using
Table 4. Agonist responses for ligands with biphasic responses at the wildtype and polymorphic variants of the b1-adrenoceptor.
Log EC50 Site 1 Log EC50 Site 2 % Site 1 % isoprenaline n
Pindolol
WT Ser49/Gly389 28.9360.11 26.1760.24 45.663.7 14.562.3 5
Gly49/Gly389 28.8760.06 26.0360.11 42.262.6 13.760.9 5
Ser49/Arg389 28.9060.06 26.1360.08 50.463.9 34.661.7 5
Bucindolol
WT Ser49/Gly389 29.4660.03 27.5360.05 59.862.8 24.664.1 5
Gly49/Gly389 29.3860.10 27.4560.11 51.562.4 25.760.8 5
Ser49/Arg389 29.3560.06 26.9860.19 80.462.6 53.661.2 5
Carvedilol
WT Ser49/Gly389 29.7160.15 27.2360.10 52.165.7 5.861.1 8
Gly49/Gly389 29.3460.05 27.3760.12 47.261.8 4.360.5 9
Ser49/Arg389 29.2360.05 27.2460.07 54.262.3 17.864.8 8
Log EC50 values for ligands having a biphasic concentration response curve at the wildtype human b1-adrenoceptor and polymorphic variants. The % of the response
occurring at site 1 and % maximum isoprenaline response for the overall response is also given. Values are mean 6 s.e.mean of n separate determinations.
doi:10.1371/journal.pone.0077582.t004
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Figure 6. The effect of pre-incubation with pertussis toxin on 3H-cAMP accumulation responses. 3H-cAMP accumulation in A CHO cells
expressing the human adenosine A1 receptor, B and E wildtype b1-adrenoceptor cells, C and F Gly49/Gly389 cells and D and G Ser49/Arg389 cells.
All cells were subjected to 24 hours in serum free media before experimentations, those with closed circles in the absence of PTX and those with
open circles in the presence of PTX. Bars represent A basal 3H-cAMP accumulation and that in response to 10 mM forskolin, B–G basal 3H-cAMP
accumulation and that in response to 10 mM isoprenaline following incubation in serum free media without and with PTX. Data points are mean 6
s.e.mean of triplicate determinations and these single experiments are representative of 4 separate experiments in each case. A demonstrates that
the PTX pre-incubation was successfully preventing the Gi-coupled responses to cyclopentyladenosine (CPA) in CHO cells expressing the human A1
adenosine receptor, however there was no effect of PTX pre-incubation on the cimaterol (catecholamines conformation) or CGP 12177 (secondary
conformation) responses occurring via the wildtype human b1-adrenoceptor or the polymorphic variants.
doi:10.1371/journal.pone.0077582.g006
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equation 5:
DR~1z
B½ 
KD
ð5Þ
where DR (dose ratio) is the ratio of the agonist concentration
required to stimulate an identical response in the presence and
absence of a fixed concentration of antagonist [B].
When CGP 12177 was used as an antagonist, clear partial
agonism was seen (Figure 3). Here, the affinity was calculated by
the method of Stephenson [52] using equation 6:
KD partial agonist~
Yx½P
1{Y
where Y~
A2½ { A1½ 
A3½  ð6Þ
where [P] is the concentration of CGP 12177, [A1] is the
concentration of cimaterol at the point where CGP 12177 alone
causes the same response, [A2] is the concentration of cimaterol
causing a given response above that achieved by CGP 12177 and
[A3] the concentration of cimaterol, in the presence CGP 12177,
causing the same stimulation as [A2].
Several of the responses were, however, best described by a two-
site concentration response using equation 7 (e.g. Figure 5, Table 4)
% maximal stimulation~
½AxN
(½AzEC150)z
½Ax(100{N)
(½AzEC250 ð7Þ
where N is the percentage of site 1, [A] is the concentration of
agonist and EC150 and EC250 are the respective EC50 values for
the two agonist sites.
A two-site analysis was also used for the experiments shown in
Figure 4 using equation 8:
Response~
Basalz(Ag{Basal) 1{
½P
(½PzIC50)
 
zPAg
½P
(½PzEC50)
 ð8Þ
where basal is the response in the absence of cimaterol, Ag is the
response to a fixed concentration of cimaterol, [P] is the
concentration of the partial agonist CGP 12177, IC50 is the
concentration of CGP 12177 that inhibits 50% of the response to
cimaterol, PAg is the maximum stimulation by CGP 12177 and
EC50 is the concentration of CGP 12177 that stimulated a half
maximal CGP 12177 response.
All data are presented as mean 6 s.e.m. of triplicate
determinations (except saturation binding experiments where
determinations were from quadruplicate wells) and n in the table
and text refers to the number of separate experiments.
Supporting Information
Figure S1 3H-inositol phosphate accumulation in cells
expressing the wildtype b1-adrenoceptor and poly-
morphic variants. 3H-inositol phosphate accumulation in A
wildtype cells, B Gly49/Gly389 cells and C Ser49/Arg389
cells. Bars are mean 6 s.e.mean of triplicate determinations.
These single experiments are representative of 4 separate
experiments in each case and demonstrate a lack of Gq-
coupled inositol phosphate accumulation in response to
b-adrenoceptor ligands.
(TIF)
Figure S2 MAPKinase activation of the wildtype b1-
adrenoceptor and polymorphic variants. MAPKinase
activation in A wildtype cells, B Gly49/Gly389 cells and C
Ser49/Arg389 cells. Bars are mean 6 s.e.mean of triplicate
determinations. These single experiments are representative
of 3 separate experiments in each case and demonstrate a
lack of ERK1/2 MAPKinase stimulation by b-adrenoceptor
ligands.
(TIF)
Figure S3 Correlation plot and statistical analysis for
the affinity of all the ligands from Table S1 in File S1 for
the WT (clone T88 x-axis) and WT (clone T3), polymor-
phic variants, and transient populations (y-axis). The
linear regression lines are not shown on the graph to ensure that
the symbols are still visible. This shows that the affinity of ligands
for the different b1-adrenoceptor variants is similar to that for the
wildtype receptor.
(TIF)
File S1 Table S1, Affinity of b-adrenoceptor ligands for
the wildtype and polymorphic variants of the b1-
adrenoceptor. Table S2, Affinity of b-adrenoceptor
ligands for the wildtype and polymorphic variants of
the b1-adrenoceptor in transiently transfected popula-
tions. Table S3, Agonist responses occurring via the
wildtype and polymorphic variants of the b1-adrenocep-
tor. Table S4, Agonist responses for ligands with
biphasic responses at the wildtype and polymorphic
variants of the b1-adrenoceptor in two additional stable
cell lines for each receptor and transiently transfected
cells. Table S5, Relationship between receptor expres-
sion level and efficacy of partial agonists at the two
agonist conformations of the wildtype and polymorphic
variants of the b1-adrenoceptor.
(DOC)
Acknowledgments
We thank June McCulloch and Marleen Groenen for technical assistance
in running the cAMP chromatography columns and Nicola Hawley for
assistance with the molecular biology.
Author Contributions
Conceived and designed the experiments: JGB. Performed the experi-
ments: JGB RGWP. Analyzed the data: JGB RGWP. Contributed
reagents/materials/analysis tools: JGB SJH. Wrote the paper: JGB SJH.
References
1. Shin J, Johnson JA (2007) Pharmacogenetics of beta-blockers. Pharmacotherapy
27(6): 874–87.
2. Johnson JA, Liggett SB (2011) Cardiovascular pharmacogenomics of adrenergic
receptor signaling: clinical implications and future directions. Clin Pharmacol
Ther 89(3): 366–78.
3. Heitz A, Schwartz J, Velly J (1983) Beta-adrenoceptors of the human
myocardium: determination of beta 1 and beta 2 subtypes by radioligand
binding. Br J Pharmacol 80(4): 711–7.
4. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, et al. (1986) Beta 1-
and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human
ventricular myocardium: coupling of both receptor subtypes to muscle
contraction and selective beta 1-receptor down-regulation in heart failure. Circ
Res 59(3): 297–309.
5. Brodde OE (2008) Beta-1 and beta-2 adrenoceptor polymorphisms: functional
importance, impact on cardiovascular diseases and drug responses. Pharmacol
Ther 117(1): 1–29.
Pharmacology of b1-Adrenoceptor Polymorphisms
PLOS ONE | www.plosone.org 11 November 2013 | Volume 8 | Issue 11 | e77582
6. Maqbool A, Hall AS, Ball SG, Balmforth AJ (1999) Common polymorphisms of
beta1-adrenoceptor: identification and rapid screening assay. Lancet 353(9156):
897.
7. Bo¨rjesson M, Magnusson Y, Hjalmarson A, Andersson B (2000) A novel
polymorphism in the gene coding for the beta(1)-adrenergic receptor
associated with survival in patients with heart failure. Eur Heart J 21(22):
1853–8.
8. Mason DA, Moore JD, Green SA, Liggett SB. (1999) A gain-of-function
polymorphism in a G-protein coupling domain of the human beta1-adrenergic
receptor. J Biol Chem 74(18): 12670–12674.
9. Tesson F, Charron P, Peuchmaurd M, Nicaud V, Cambien F, et al. (1999)
Characterization of a unique genetic variant in the beta1-adrenoceptor gene and
evaluation of its role in idiopathic dilated cardiomyopathy. CARDIGENE
Group. Mol Cell Cardiol 31(5): 1025–32.
10. Levin MC, Marullo S, Muntaner O, Andersson B, Magnusson Y (2002) The
myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits
constitutive activity and increased desensitization and down-regulation. J Biol
Chem 277(34): 30429–30435.
11. Rathz DA, Brown KM, Kramer LA, Liggett SB (2002) Amino acid 49
polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted
trafficking. J Cardiovasc Pharmacol 39(2): 155–60.
12. Magnusson Y, Levin MC, Eggertsen R, Nystro¨m E, Mobini R, et al. (2005)
Ser49Gly of beta1-adrenergic receptor is associated with effective beta-
blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther 78(3): 221–
231.
13. Biolo A, Clausell N, Santos KG, Salvaro R, Ashton-Prolla P, et al. (2008) Impact
of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure,
arrhythmogenesis, prognosis, and response to beta-blocker therapy. Am J Cardiol
102(6): 726–732.
14. Nicoulina S, Shulman V, Shesternya P, Chernova A, Salmina A, et al.(2010)
Association of ADRB1 gene polymorphism with atrial fibrillation. Genet Test
Mol Biomarkers 14(2): 249–53.
15. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, et al. (2003) Beta
1-adrenergic receptor polymorphisms and antihypertensive response to meto-
prolol. Clin Pharmacol Ther 74(1): 44–52.
16. Liu J, Liu ZQ, Yu BN, Xu FH, Mo W, et al. (2006) beta1-Adrenergic receptor
polymorphisms influence the response to metoprolol monotherapy in patients
with essential hypertension. Clin Pharmacol Ther 80(1): 23–32.
17. Joseph SS, Lynham JA, Grace AA, Colledge WH, Kaumann AJ (2004)
Markedly reduced effects of (-)-isoprenaline but not of (-)-CGP12177 and
unchanged affinity of beta-blockers at Gly389-beta1-adrenoceptors compared to
Arg389-beta1-adrenoceptors. Br J Pharmacol 142: 51–6.
18. Huntgeburth M, La Rose´e K, ten Freyhaus H, Bo¨hm M, Schnabel P, et al.
(2011) The Arg389Gly b1-adrenoceptor gene polymorphism influences the
acute effects of b-adrenoceptor blockade on contractility in the human heart.
Clin Res Cardiol 100(8): 641–7.
19. McLean RC, Baird SW, Becker LC, Townsend SN, Gerstenblith G, et al. (2012)
Response to catecholamine stimulation of polymorphisms of the beta-1 and
beta-2 adrenergic receptors. Am J Cardiol 110(7): 1001–7
20. Liu J, Liu ZQ, Tan ZR, Chen XP, Wang LS, et al. (2003) Gly389Arg
polymorphism of beta1-adrenergic receptor is associated with the cardiovascular
response to metoprolol. Clin Pharmacol Ther 74(4): 372–9.
21. Sofowora GG, Dishy V, Muszkat M, Xie HG, Kim RB, et al. (2003) A common
beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure
response to beta-blockade. Clin Pharmacol Ther 73(4): 366–71.
22. Cresci S, Kelly RJ, Cappola TP, Diwan A, Dries D, et al. (2009) Clinical and
genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol 54(5):
432–44.
23. Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, et al.
(2003) Beta 1-adrenergic receptor polymorphisms confer differential function
and predisposition to heart failure. Nat Med 9(10): 1300–5.
24. Terra SG, Hamilton KK, Pauly DF, Lee CR, Patterson JH, et al. (2005)
Beta1-adrenergic receptor polymorphisms and left ventricular remodeling
changes in response to beta-blocker therapy. Pharmacogenet Genomics 15(4):
227–34.
25. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, et al.
(2006) A polymorphism within a conserved beta(1)-adrenergic receptor motif
alters cardiac function and beta-blocker response in human heart failure. Proc
Natl Acad Sci U S A 103(30): 11288–93.
26. Molenaar P, Chen L, Semmler AB, Parsonage WA, Kaumann AJ (2007)
Human heart beta-adrenoceptors: beta1-adrenoceptor diversification
through ‘affinity states’ and polymorphism. Clin Exp Pharmacol Physiol
34: 1020–8.
27. Petersen M, Andersen JT, Hjelvang BR, Broedbaek K, Afzal S, et al.(2011)
Association of beta-adrenergic receptor polymorphisms and mortality in
carvedilol-treated chronic heart-failure patients. Br J Clin Pharmacol
71(4):556–65.
28. Liu WN, Fu KL, Gao HY, Shang YY, Wang ZH, et al. (2012) b1 adrenergic
receptor polymorphisms and heart failure: a meta-analysis on susceptibility,
response to b-blocker therapy and prognosis. PLoS One 7(7):e37659.
29. Parvez B, Chopra N, Rowan S, Vaglio JC, Muhammad R, et al. (2012) A
common b1-adrenergic receptor polymorphism predicts favorable response
to rate-control therapy in atrial fibrillation. J Am Coll Cardiol 59(1): 49–
56.
30. Rau T, Du¨ngen HD, Edelmann F, Waagstein F, Lainsˇcˇak M, et al. (2012)
Impact of the b1-adrenoceptor Arg389Gly polymorphism on heart-rate
responses to bisoprolol and carvedilol in heart-failure patients. Clin Pharmacol
Ther 92(1): 21–8.
31. Aleong RG, Sauer WH, Robertson AD, Liggett SB, Bristow MR (2013)
Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias
with bucindolol in patients with chronic heart failure. Circ Arrhythm
Electrophysiol 6(1):137–43.
32. O’Shaughnessy KM, Fu B, Dickerson C, Thurston D, Brown MJ (2000) The
gain-of-function G389R variant of the beta1-adrenoceptor does not influence
blood pressure or heart rate response to beta-blockade in hypertensive subjects.
Clin Sci (Lond) 99(3): 233–8.
33. Karlsson J, Lind L, Hallberg P, Michae¨lsson K, Kurland L, et al. (2004) Beta1-
adrenergic receptor gene polymorphisms and response to beta1-adrenergic
receptor blockade in patients with essential hypertension. Clin Cardiol 27(6):
347–350.
34. de Groote P, Lamblin N, Helbecque N, Mouquet F, Mc Fadden E, et
al. (2005) The impact of beta-adrenoreceptor gene polymorphisms on
survival in patients with congestive heart failure. Eur J Heart Fail 7(6):
966–73.
35. Metra M, Covolo L, Pezzali N, Zaca` V, Bugatti S, et al. (2010) Role of beta-
adrenergic receptor gene polymorphisms in the long-term effects of beta-
blockade with carvedilol in patients with chronic heart failure. Cardiovasc Drugs
Ther 24(1): 49–60.
36. Davis HM, Johnson JA (2011) Heart failure pharmacogenetics: past, present,
and future. Curr Cardiol Rep 13(3):175–84.
37. Petersen M, Andersen JT, Jimenez-Solem E, Broedbaek K, Hjelvang BR, et al.
(2012) Effect of the Arg389Gly b1-adrenoceptor polymorphism on plasma renin
activity and heart rate, and the genotype-dependent response to metoprolol
treatment. Clin Exp Pharmacol Physiol 39(9): 779–85.
38. Granneman JG (2001) The putative beta4-adrenergic receptor is a novel state
of the beta1-adrenergic receptor. Am J Physiol Endocrinol Metab 280: E199–
202.
39. Molenaar P (2003) The ‘state’ of beta-adrenoceptors. Br J Pharmacol 140: 1–2.
40. Arch JR (2004) Do low-affinity states of beta-adrenoceptors have roles in
physiology and medicine? Br J Pharmacol 143: 517–518.
41. Kaumann AJ, Molenaar P (2008) The low-affinity site of the beta1-adrenoceptor
and its relevance to cardiovascular pharmacology. Pharmacol Ther 118: 303–
336.
42. Konkar AA, Zhu Z Granneman JG (2000) Aryloxypropanolamine and
catecholamine ligand interactions with the b1-adrenergic receptor: evidence
for interaction with distinct conformations of b1-adrenergic receptors.
J Pharmacol Exp Ther 294: 923–932.
43. Baker JG, Hall IP, Hill SJ (2003) Agonist actions of ‘‘b-blockers’’ provide
evidence for two agonist activation sites or conformations of the human b1-
adrenoceptor. Mol Pharmacol 63: 1312–1321.
44. Joseph SS, Lynham JA, Molenaar P, Grace AA, Colledge WH, et al. (2003)
Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-
propranolol-resistant site of the beta1-adrenoceptor in human atrium and
recombinant receptors. Naunyn Schmiedebergs Arch Pharmacol 368: 496–503.
45. Baker JG (2005) Sites of action of b-ligands at the human b1-adrenoceptor.
J Pharmacol Exp Ther 313: 1163–1171.
46. Baker JG (2010) The selectivity of b-adrenoceptor agonists at the human b1, b2
and b3 adrenoceptors. Br J Pharmacol 160: 1048–1061.
47. Jasper JR, Michel MC, Insel PA (1988) Molecular mechanism of beta-adrenergic
receptor blockers with intrinsic sympathomimetic activity. FASEB J 2: 2891–
2894.
48. Jasper JR, Michel MC, Insel PA (1990) Amplification of cyclic AMP generation
reveals agonistic effects of certain beta-adrenergic antagonists. Mol Pharmacol
37: 44–49.
49. Baker JG, Hill SJ (2007) A comparison of the antagonist affinities for the Gi and
Gs-coupled states of the human adenosine A1 receptor. J Pharmacol Exp Ther
320: 218–228.
50. Lowry OH, Rosebrough NJ, Farr AC, Randall RJ (1951) Protein measurements
with the folin phenol reagent. J Biol Chem 193: 265–275.
51. Megson AC, Walker EM, Hill SJ (2001) Role of protein kinase Ca in
signalling from the histamine H1-receptor to the nucleus. Mol Pharmacol 59:
1012–1021
52. Stephenson RP (1956) A modification of receptor theory. Br J Pharmacol 11:
5109–5116.
53. Walter M, Lemoine H, Kaumann AJ (1984) Stimulant and blocking effects
of optical isomers of pindolol on the sinoatrial node and trachea of guinea
pig. Role of beta-adrenoceptor subtypes in the dissociation between
blockade and stimulation. Naunyn Schmiedebergs Arch Pharmacol 327:
159–175.
54. Galandrin S, Bouvier M (2006) Distinct signaling profiles of beta1 and beta2
adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated
protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 70(5):
1575–1584.
55. Small KM, McGraw DW, Liggett SB (2003) Pharmacology and physiology of
human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 43:
381–411.
Pharmacology of b1-Adrenoceptor Polymorphisms
PLOS ONE | www.plosone.org 12 November 2013 | Volume 8 | Issue 11 | e77582
56. Iredale PA, Hill SJ (1993) Increases in intracellular calcium via activation of an
endogenous P2-purinoceptor in cultured CHO-KI cells. Br J Pharmacol 110:
1305–1310
57. Azzi M, Charest PG, Angers S, Rosseau G, Kohout T, et al. (2003) Beta-arrestin-
mediated activation of MAPK by inverse agonists reveals distinct active conformations
for G protein-coupled receptors. Proc Natl Acad Sci USA 100: 11406–11.
58. Baker JG, Hall IP, Hill SJ (2003) Agonist and inverse agonist actions of ‘‘b-
blockers’’ at the human b2-adrenoceptor provide evidence for agonist-directed
signalling. Mol Pharmacol 64: 1357–1369.
59. Baker JG, Hill SJ (2007) Multiple GPCR conformations and signalling pathways:
Implications for antagonist affinity estimates. Trends Pharmacol Sci 28: 374–
381.
Pharmacology of b1-Adrenoceptor Polymorphisms
PLOS ONE | www.plosone.org 13 November 2013 | Volume 8 | Issue 11 | e77582
